Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer
Status:
Completed
Trial end date:
2002-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of post-operative high-dose bolus
interleukin-2 (IL-2) in patients with high-risk renal cell carcinoma (RCC).